Study of a new immune drug for resistant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that got worse after trying standard treatments.
- You have been treated with an immunotherapy (such as Keytruda or Opdivo) and your cancer progressed.
- You are able to carry out daily activities with little to no help (performance status 0 or 1).
- Your kidneys, liver, and blood counts work well enough (confirmed by blood tests).
- You are willing to have a biopsy and give blood samples as part of the study.
- You do not have active autoimmune disease, active hepatitis or HIV, or uncontrolled other illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This trial tests a new drug combined with chemotherapy compared to a standard immunotherapy combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the new combination is more effective and may offer a new first-line treatment option.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.